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Abstract
Background: Hepatitis C virus (HCV) is one of the main causes of liver-related morbidity and
mortality. Although combined interferon-α-ribavirin therapy is effective for about 50% of the
patients with HCV, better therapies are needed and preventative vaccines have yet to be
developed. Short-hairpin RNAs (shRNAs) inhibit gene expression by RNA interference. The
application of transient shRNA expression is limited, however, due to the inability of the shRNA
to replicate in mammalian cells and its inefficient transduction. The duration of transgene (shRNA)
expression in mammalian cells can be significantly extended using baculovirus-based shRNA-
expressing vectors that contain the latent viral protein Epstein-Barr nuclear antigen 1 (EBNA1) and
the origin of latent viral DNA replication (OriP) sequences. These recombinant vectors contain
compatible promoters and are highly effective for infecting primary hepatocyte and hepatoma cell
lines, making them very useful tools for studies of hepatitis B and hepatitis C viruses. Here, we
report the use of these baculovirus-based vector-derived shRNAs to inhibit core-protein
expression in full-length hepatitis C virus (HCV) replicon cells.
Results: We constructed a long-term transgene shRNA expression vector that contains the EBV
EBNA1 and OriP sequences. We also designed baculovirus vector-mediated shRNAs against the
highly conserved core-protein region of HCV. HCV core protein expression was inhibited by the
EBNA1/OriP baculovirus vector for at least 14 days, which was considerably longer than the 3 days
of inhibition produced by the wild-type baculovirus vector.
Conclusion:  These findings indicate that we successfully constructed a long-term transgene
(shRNA) expression vector (Ac-EP-shRNA452) using the EBNA1/OriP system, which was
propagated in Escherichia coli and converted into mammalian cells. The potential anti-HCV activity
of the long-term transgene (shRNA) expression vector was evaluated with the view of establishing
highly effective therapeutic agents that can be further developed for HCV gene therapy
applications.
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Background
Infection by the hepatitis C virus (HCV) is a major public-
health problem, with 170 million people chronically
infected worldwide [1,2]. The current treatment with
combined interferon-ribavirin therapy fails to cure the
infection in 30% to 50% of cases [3,4], particularly those
with HCV genotypes 1 and 2. Chronic infection with HCV
results in liver cirrhosis and can lead to hepatocellular car-
cinoma [5,6]. Although combined interferon-α-ribavirin
therapy is effective for about 50% of the patients infected
with HCV, better therapies are needed and preventative
vaccines have yet to be developed. In an effort to develop
an alternative to combined interferon-ribavirin treatment,
we used RNA interference based on short-hairpin RNA
(shRNA), which is a powerful tool for suppressing gene
function [7]. Small interference RNAs (siRNAs) directed
against HCV are likely to successfully block the replication
cycle because HCV is an RNA virus and replicates in the
cytoplasm of liver cells without integration into the host
genome.
The ability of baculoviruses, including Autographa califor-
nica multiple nuclear polyhedrosis virus (AcMNPV), to infect
insect cells has led to their use in multiple protein expres-
sion systems [8,9] and as plant insecticides [10]. AcMNPV,
the genome of which comprises a circular, double-
stranded DNA that contains ~130 Kbp [11] surrounded by
a large envelope, infects a variety of mammalian cell
types, with the exception of certain hematopoietic cell
lines, although its genome does not replicate or integrate
into mammalian chromosomes [12,13]. In particular, the
inability of baculoviruses to replicate in mammalian cells
makes them attractive candidate vectors for in vitro gene
therapy studies [14,15]. These recombinant vectors con-
tain compatible promoters and are highly effective in
infecting primary hepatocyte and hepatoma cell lines,
making them very useful tools for studies of hepatitis B
and hepatitis C viruses [16-18].
A major limitation of the baculoviral transduction vector,
however, is the short duration of transgene expression.
Because the baculovirus genome cannot replicate in mam-
malian cells, it is usually lost or diluted soon after infection.
The efficiency of transgene expression must be substantially
increased to be applicable for human gene therapy [19].
The Epstein Barr virus (EBV) plasmid is a replicating episo-
mal vector that has been developed to overcome the prob-
lem of rapid elimination of intracellularly-delivered
plasmid DNA in nonviral vector-mediated gene transfer.
EBV is a gamma herpes virus that is maintained as a ~172-
kb episome in a small ratio of resting B cells and epithelial
cells in most of the human population. EBV induces latent
infection in human B cells [20]. When EBV infects cells, the
linear and double-stranded genomes are circularized and
sustained as a stable episome. The EBV replication system
is present at about 1~100 copies per cell [21], and separates
by non-covalent attachment to the host chromosome. The
EBV replicon vector system has been used to study long-
term transgene expression [22,23]. The origin for latent
viral DNA replication (OriP) [24] and the latent viral pro-
tein Epstein-Barr nuclear antigen 1 (EBNA1) [21] are essen-
tial for the replication of EBV [25]. The EBNA1/OriP
elements have been successfully exploited to achieve dura-
ble expression of foreign genes with plasmid- or virus-
based expression systems [26-30].
Previously, we demonstrated efficient inhibition of intracel-
lular HCV replication by baculovirus-based shRNA-express-
ing vectors [31]. This expression system is transient,
however, and therefore unable to provide long-term expres-
sion of the shRNA. We hypothesized that long-term trans-
gene (shRNA) expression can be significantly improved in
mammalian cells using baculovirus-based shRNA-express-
ing vectors containing EBNA1/OriP sequences.
In the present study, we constructed a long-term transgene
(shRNA) expression vector (Ac-EP-shRNA452) using the
EBNA1/OriP system, which was propagated in Escherichia
coli and converted into mammalian cells. The potential
anti-HCV activity of the long-term transgene (shRNA)
expression vector was evaluated with the view of estab-
lishing highly effective therapeutic agents that can be fur-
ther developed for HCV gene therapy applications.
Results
Construction of baculovirus transfer vectors carrying 
shRNA-synthesizing cassettes
The core-protein forms the nucleocapsid and modulates
gene transcription, cell proliferation, and apoptosis. HCV
functions as an mRNA with a single-stranded RNA
genome; thus, we hypothesized that cleavage of the core-
protein mRNA would inhibit nuclear transport and virus
duplication. We previously reported the design of baculo-
virus vectors expressing shRNA against the following
region of the HCV: 452-472, which contains the nuclear
localization signal site of the HCV core region (Figure 1A,
B) [31]. This vector cannot, however, induce long-term
shRNA expression. Therefore, we constructed a long-term
transgene shRNA expression vector that contains the EBV
EBNA1  and  OriP  sequences (Figure 1C). Recombinant
baculovirus containing the shRNA genome (Ac-shRNA
and Ac-EP-shRNA) was generated by homologous recom-
bination of the transfer vector and linearized baculovirus
DNAs (BD Biosciences, San Jose, CA) in Sf9 cells. Viruses
were produced at high titers, ranging from 2.0 × 108 to 4.5
× 108 pfu/ml.
Inhibition of HCV RNA replication of EBNA1/OriP 
baculovirus-mediated shRNA-expression vectors in the 
HCV replicon
We investigated whether the intracellular expression of
shRNA inhibited viral replication and affected HCV RNAVirology Journal 2009, 6:156 http://www.virologyj.com/content/6/1/156
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levels in NNC#2 cells. The baculovirus-infection effi-
ciency of NNC#2 cells ranged from 80% to 90% [31].
Real-time reverse transcription polymerase chain reaction
(RT-PCR) was used to examine the ability to silence RNA
in NNC#2 cells 3 days post-infection. When NNC#2 cells
were infected with Ac-shRNAs at a multiplicity of infec-
tion (MOI) of 50 and 100, HCV RNA levels were signifi-
cantly reduced compared with a scrambled shRNA
control. Two of the constructs, Ac-shRNA452 (55%, MOI
50; 71%, MOI 100) and Ac-EP-shRNA452 (55%, MOI 50;
67%, MOI 100), inhibited the HCV RNA levels (Figure
2A). In contrast, the control baculovirus vector (Ac-EP-
control-shRNA) did not inhibit HCV replication (Figure
2A). These findings indicated that the shRNA had a
sequence-specific inhibitory effect on HCV replication.
We next used the CLEIA assay to examine whether shRNA
against the HCV core protein inhibited viral replication.
When NNC#2 cells were infected with Ac-shRNAs at MOIs
of 50 and 100, core-protein expression was significantly
reduced compared with a non-related shRNA control (Fig-
ure 2B). The Ac-EP-control-shRNA baculovirus vectors
had no inhibitory effect on HCV replication.
Enhanced baculovirus-mediated shRNA effects were 
observed in the presence of EBNA1/OriP
To investigate the effect of EBNA/OriP on shRNA expres-
sion, we examined the inhibition of HCV replication by
Ac-shRNA452 and Ac-EP-shRNA452 in NNC#2 cells for
14 days. When NNC#2 cells were infected with either Ac-
shRNA452 or Ac-EP-shRNA452 at an MOI of 100, core-
protein expression was significantly reduced compared
with a scrambled shRNA control (Ac-EP-control-shRNA)
for 3 days (data not shown). Both Ac-shRNA452 and Ac-
EP-shRNA inhibited HCV replication for 3 days (Figure
3A). After 3 days, however, cells infected with Ac-
shRNA452 exhibited a steady increase in HCV RNA
expression while those infected with Ac-EP-shRNA452
continued to have low HCV RNA expression for at least 14
days (Figure 3A). Infection of the NNC#2 cells with
recombinant baculovirus vectors containing genetic ele-
ments from EBV, EBNA1, and OriP did not induce cellular
toxicity, as determined with a bromodeoxyuridine
(BrdU)-based colorimetric assay (Figure 3B). These results
suggest that HCV RNA expression was more effectively
inhibited by the EBNA/OriP baculovirus vector than by
the wild-type baculovirus vector.
Production of EBNA1 protein and siRNA by baculovirus-
based shRNA-expressing vectors containing EBNA1/OriP 
sequences
We first used Western blot analysis to detect EBNA1 pro-
tein in Ac-EP-shRNA-infected cells (Figure 4A). EBNA1
protein was detected in the Ac-EP-shRNA-infected cells.
Then, to investigate whether HCV core gene-targeting shR-
NAs can be digested to mono-specific products of the
expected size, siRNAs were analyzed by Northern blot
analysis of shRNA-expressing NNC#2 cells. The siRNAs
from both Ac-shRNA452 and Ac-EP-shRNA452 yielded
products of ~20 nt, which is the expected size of mono-
meric siRNAs, for 3 days (Figure 4B). The siRNA band in
A Genomic profile of HCV showing both coding and non-coding genes Figure 1
A Genomic profile of HCV showing both coding and non-coding genes. B HCV core region target sites and 
sequences used for the design of shRNAs. C Construction and schematic representation of EBNA1/OriP baculovirus transfer 
vector expressing HCV core shRNA.Virology Journal 2009, 6:156 http://www.virologyj.com/content/6/1/156
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Ac-shRNA452-infected cells, however, became undetecta-
ble after 5 days. In contrast, siRNA in Ac-EP-shRNA452-
infected cells could be detected for at least 14 days.
Discussion
There is high demand for the development of effective
anti-HCV drugs. Gene silencing by RNA interference is a
promising approach to elucidate gene function and to
inhibit certain RNA viruses such as HCV [32-34]. Delivery
of siRNA to the appropriate cells or tissues, however, is a
major challenge. Several approaches have been described
for generating loss-of function phenotypes in mammalian
systems using siRNA, but these techniques are limited and
are not suitable for generating a long-term silencing effect
in vivo [35,36]. Efficient and safe delivery systems have not
yet been established for the suppression of HCV replica-
tion. Baculoviruses appear to be useful viral vectors, not
only for the abundant expression of foreign genes in
insect cells, but also for efficient gene delivery to the
hepatoma lines HepG2 and Huh7 [37]. One of the major
limitations of the baculoviral transduction vector is the
short duration of transgene expression. The EBNA1/OriP
system has been widely exploited in many different vec-
tors and cell lines. The findings suggest that the EBNA1/
OriP system is effective and useful for long-term and high-
level transgene expression.
In this study, recombinant baculovirus vectors containing
genetic elements from EBV, EBNA1/OriP, which are
essential for the episomal maintenance of the EBV
genome in latently infected cells, were constructed and
tested for their ability to sustain and express the transgene
(enhanced HCV core gene-targeting shRNAs) in HCV rep-
licon cells. The introduction of wild-type or EBNA1/OriP-
baculovirus-mediated sh452 into target cells containing
HCV replicon RNA induced a dose-related reduction in
the level of HCV RNA at 3 days. The effectiveness of the
inhibition of HCV replication, however, did not differ
under the control of the two different vectors (Ac-
shRNA452 or Ac-EP-shRNA452).
To investigate the long-term effect of EBNA/OriP on
shRNA expression, we examined the inhibition of HCV
replication by Ac-shRNA452 and Ac-EP-shRNA452 in
NNC#2 cells for 14 days. Both Ac-shRNA452 and Ac-EP-
shRNA inhibited HCV replication for 3 days. After 3 days,
however, cells infected with Ac-shRNA452 exhibited a
steady increase in HCV RNA expression while those
Inhibition of HCV RNA by EBNA1/OriP and wild-type baculovirus-mediated sh452 Figure 2
Inhibition of HCV RNA by EBNA1/OriP and wild-type baculovirus-mediated sh452. A Real time PCR analysis of 
HCV RNA expression after transduction of HCV full replicon cells (NNC#2, 4 × 104 cells/well) with an MOI 50 and 100 bacu-
lovirus-mediated shRNA. HCV RNA values relative to the scrambled shRNA control are shown. B Inhibition of HCV replica-
tion by baculovirus-mediated core shRNAs. Ac-shRNAs were used to infect HCV replicons and intracellular HCV core protein 
levels measured after 3 days by an HCV protein antigen CLEIA assay. Error bars represent standard errors of the mean from 
three experiments. *p < 0.01.Virology Journal 2009, 6:156 http://www.virologyj.com/content/6/1/156
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infected with Ac-EP-shRNA452 continued to have low
HCV RNA expression for at least 14 days. These recom-
binant baculovirus vectors containing genetic elements
from EBV, EBNA1, and OriP did not induce cellular toxic-
ity in the NNC#2 cells, as determined with a BrdU-based
colorimetric assay. The HCV RNA was inhibited by
EBNA1/OriP baculovirus-mediated shRNA452 for a
longer time by the EBNA1/OriP baculovirus vector than
by the wild-type baculovirus vector.
To investigate whether EBNA1/OriP baculovirus-medi-
ated shRNA452 can be digested to mono-specific prod-
ucts of expected size, monomeric siRNAs were performed
by Northern blot analysis in AB1-shRNA expressing
NNC#2 cells. The shRNAs yielded products ~20 nt, the
expected size of monomeric siRNAs, over the long term.
Furthermore, EBNA1 protein was also detected in the Ac-
EP-shRNA-infected cells. These findings indicated a direct
correlation between the level of the virus and siRNA or
EBNA1 production.
Conclusion
The results of the present study indicate that we have suc-
cessfully constructed a long-term transgene (shRNA)
expression vector (Ac-EP-shRNA452) using the EBNA1/
OriP system, which was propagated in Escherichia coli and
converted into mammalian cells. The potential anti-HCV
activity of the long-term transgene (shRNA) expression
vector was evaluated with the view of establishing highly
effective therapeutic agents that can be further developed
for HCV gene therapy applications.
Methods
Cell culture
NNC#2 (NN/1b/FL) cells [38] carrying a full genome rep-
licon were cultured in Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum,
non-essential amino-acids, L-glutamine, and 1 mg/ml
G418 (Invitrogen, Carlsbad, CA).
Northern blot analysis
Total RNA was extracted from Ac-shRNA452 infected
Huh7 cells using a mirVana™ miRNA Isolation Kit,
according to the manufacturer's instructions (Roche Diag-
nostics GmbH, Mannheim, Germany). Small RNAs (5 μg)
were loaded onto a 15% (w/v) polyacrylamide/7 M urea
gel. After transfer to a Hybond-N™ nylon membrane (GE
Healthcare Bio-Sciences Corp., Piscataway, NJ), synthetic
locked nucleic acid (LNA)/DNA oligonucleotides (sh452:
5'-DIG-CCGCGCAGGGGCCCCAGG-3') complementary
to the antisense strand of the shRNA452 were used as
probes. The membranes were prehybridized for 1 h in
DIG EASY hybridization buffer (Roche Diagnostics
GmbH) at 60°C and hybridized overnight to the 5'-DIG
labeled LNA/DNA probe (10 ng/ml of hybridization
buffer). Four post-hybridization washes were performed
for 20 min each at 60°C with 2× SSC (1× SSC = 0.15 M
NaCl plus 0.015 M sodium citrate-0.1% sodium dodecyl
sulfate). LNA/DNA/RNA hybrids were detected using the
CSPD chemiluminescent detection system (Roche Diag-
nostics GmbH).
Western blot analysis
Cells were lysed in 1× CAT enzyme-linked immunosorb-
ent assay buffer (Roche Diagnostics GmbH). Cell lysates
were separated by sodium dodecyl sulfate/polyacrylamide
gel electrophoresis and transferred to nitrocellulose mem-
branes, and these were blocked with PVDF Blocking Rea-
gent (TOYOBO, Ohsaka, Japan). The primary antibodies
used were monoclonal antibodies against EBNA1 (Acris
Antibodies GmbH) and G3PDH (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA). Horseradish peroxidase-conju-
Long-term inhibition of HCV RNA by EBNA1/OriP and wild- type baculovirus-mediated sh452 Figure 3
Long-term inhibition of HCV RNA by EBNA1/OriP 
and wild-type baculovirus-mediated sh452. A Real-
time RT-PCR analysis of HCV RNA expression after trans-
duction of HCV full replicon cells (NNC#2, 4 × 104 cells/
well) with Ac-shRNA452 (MOI = 100 [circle]), Ac-EP-
shRNA452 (MOI = 100 [square]). B The cytotoxicity of Ac-
EP-shRNA452 (square) and Ac-shRNA452 (circle) repre-
sented as the percentage reduction of viable Huh-7 cells. A 
cytotoxicity assay was performed using a BrdU Cell Prolifer-
ation ELISA kit according to the manufacturer's instructions 
(Roche Diagnostics GmbH). The toxicity results are repre-
sentative of three independent experiments.Virology Journal 2009, 6:156 http://www.virologyj.com/content/6/1/156
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gated anti-goat antibody (Sigma Chemical Co., St. Louis,
MO) was used as the secondary antibody.
RNA purification and real-time RT-PCR
Total RNA was isolated from the cells using a mirVana
miRNA Isolation Kit (Ambion, Austin, TX). Real-time RT-
PCR was performed using the following primers located
in the HCV core region: forward primer (813-833 nt), 5'-
CTGGAGGACGGCGTGAATTAT-3'; reverse primer (938-
957 nt), 5'-CGTTCGTGACATGGTATATC-3'. HCV-specific
RNA was detected by real-time PCR as an increase in SYBR
Green I fluorescence on an ABI PRISM 7700 (Applied Bio-
systems, Foster City, CA). The 18S rRNA housekeeping
gene was used as a control for normalization. Each real-
time PCR assay was performed in triplicate.
Cytotoxicity assay
NNC#2 cells (2 × 104 cells/mL) were seeded into 96-well
microtiter plates and incubated in the presence of various
concentrations of the test compounds. The dilutions
ranged from 1 to 5-fold, and 9 concentrations were exam-
ined. All of the experiments were performed in triplicate.
After 3 days culture at 37°C in a CO2 incubator, cell via-
bility was quantified using a colorimetric BrdU Cell Pro-
liferation enzyme-linked immunosorbent assay according
to the manufacturer's instructions (Roche Diagnostics
GmbH). The absorbances were read by a microcomputer-
controlled photometer (Titertec MultiscanR; Labsystem
Oy, Helsinki, Finland) at 405 nm. These values were then
translated into percentages per well.
Baculovirus transfer vector constructs
We designed baculovirus transfer vectors expressing shR-
NAs against the following region of the HCV core-protein
sequence: nucleotides 452-472, which contains the
nuclear localization signal site (pU6-core-shRNA452)
[31]. The following site in the core region of the common
sequence of the HCV strain M1LE (GenBank accession
number AB080299) was chosen as the target for the
shRNA: 5'-GCCGCGCAGGGGCCCCAGGUU-3'
(shRNA452). Sense and antisense strands of shRNA oligo-
nucleotides were synthesized, annealed at 95°C for 3 min,
and then slowly cooled in phosphate-buffered saline (pH
7.4, containing 50 mM NaCl). The oligonucleotides con-
tained the loop CCACACC sequence, and KpnI and
BamHI ends, which were inserted into a pU6 vector, based
on pSV2-neo. A Pol III-type U6 promoter allowed for con-
stant expression of the shRNAs. Fragments of U6-core-
sh452, ranging from the EcoRI site upstream of the U6
promoter to the BamHI site downstream of the terminat-
ing sequence, were sequenced and then inserted into the
cloning site of the baculovirus transfer vectors pVL1392
and pVL1393 (BD Biosciences, San Jose, CA) in an oppo-
site orientation to the polyhedrin promoter to create
pVL1392-core-shRNA452 and pVL1393-core-shRNA452.
A spacer was inserted between the inverted sequences to
form a hairpin structure, and to enhance its stability.
The EBV EBNA1 and OriP gene sequences were obtained
from the pCEP4 plasmid (Invitrogen). The EBNA1/OriP
sequence was digested with restriction enzymes EcoRI and
Detection of EBNA1 protein and siRNA in Ac-EP-shRNA452 infected cells Figure 4
Detection of EBNA1 protein and siRNA in Ac-EP-shRNA452 infected cells. A Western blot analysis of EBNA1 
expression in baculovirus-infected Huh7 cells. Cell lysates were prepared 7 days and 14 days post-infection from cells infected 
with different viruses. Lane 1: Ac-sh452; lane 2: Ac-EP-sh452; lane 3: Ac-EP-control-shRNA. B Expression of siRNA by a bacu-
lovirus vector. To demonstrate the intracellular expression of the shRNA construct in the respective siRNA, Huh-7 cells were 
infected with Ac-EP-shRNA452. The mixture was run on a 15% polyacrylamide TBE urea gel after 3, 7, and 14 days.Virology Journal 2009, 6:156 http://www.virologyj.com/content/6/1/156
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SalI, and inserted into the EcoRI and XhoI sites of pVAX1
(Invitrogen). The cytomegalovirus (CMV) promoter was
amplified by PCR using pCEP4 as the template. The CMV
promoter was inserted into the HindIII and EcoRI sites
upstream of the EBNA1/OriP sequence. The CMV-EBNA1/
OriP unit was digested with PmeI, and inserted into the
NaeI site of the baculovirus transfer plasmid pVL1392
(BD Biosciences) to construct pVL1392-EPCMV. Frag-
ments of U6-core-sh452, ranging from the NotI site
upstream of the U6 promoter to the BamHI site down-
stream of the terminating sequences, were sequenced and
then inserted into the cloning site of the pVL1392-EPCMV
baculovirus transfer vector to produce the plasmid
pVL1392-EP-shRNA. Scrambled shRNA (control-shRNA)
cloned into the same vector was used as a negative control
(pVL1392-EP-control-shRNA) in all experiments.
Preparation of baculoviruses
Recombinant baculovirus containing the shRNA genome
(Ac-shRNA) was generated by homologous recombina-
tion of the transfer vector and linearized baculovirus
DNAs (BD Biosciences) following previously published
procedures [39].
Measurement of HCV core protein
AcU6-HCV-core-shRNAs or Ac-EBNAU6-core-shRNAs
were used to infect HCV replicon cells. After 3 days, intra-
cellular HCV core-protein levels were measured using a
fully automated HCV core-protein antigen chemilumines-
cent enzyme immunoassay (CLEIA) according to the
manufacturer's instructions [40,41]. The relative chemilu-
minescence unit was measured and used to determine the
concentration of the HCV core antigen according to a
standard curve generated using recombinant HCV core
antigen. The concentration was expressed in units of fem-
tomole/L (fmol/L). Each CLEIA assay was performed in
triplicate.
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